10-Q: Heartflow Reports Strong Revenue Growth in Q2 2026

Heartflow, Inc. announced a 48% year-over-year revenue increase for the second quarter of 2026, driven by higher case volumes and the growing adoption of its Plaque Analysis product.

Summary

• Heartflow, Inc. reported a 48% increase in revenue for the three months ended June 30, 2026, reaching $64.1 million compared to $43.4 million in the prior year period.
• For the six months ended June 30, 2026, revenue grew by 45% to $116.7 million from $80.6 million in the same period last year.
• Gross profit for Q2 2026 increased by 62% to $53.2 million, with gross margin improving to 83% from 75% in Q2 2025.
• Operating expenses rose significantly, with R&D expenses up 75% and SG&A expenses up 42% for the quarter.
• The company incurred a net loss of $15.7 million for Q2 2026, an increase from $9.2 million in Q2 2025.
• Cash, cash equivalents, and investments totaled $246.8 million as of June 30, 2026, which management believes is sufficient for at least the next 12 months.
• An asset impairment charge of $7.5 million was recognized in March 2026 related to the Mountain View facility sublease.
• The company filed a patent infringement lawsuit against Cleerly, Inc. on April 13, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, with strong revenue growth and improving gross margins, but offset by significant operating losses and ongoing R&D investments.

Positives

• Revenue increased by 48% to $64.1 million for the three months ended June 30, 2026, compared to $43.4 million in the prior year.
• Revenue increased by 45% to $116.7 million for the six months ended June 30, 2026, compared to $80.6 million in the prior year.
• Gross margin improved to 83% for Q2 2026 from 75% in Q2 2025, driven by increased revenue case volume and AI efficiency initiatives.
• Heartflow Plaque Analysis adoption is growing, supported by expanded reimbursement coverage.
• The company has $246.8 million in cash, cash equivalents, and investments as of June 30, 2026, providing a sufficient liquidity runway for at least the next 12 months.
• Revenue case volume increased by 74% year-over-year for Q2 2026.

Negatives

• Net loss increased to $15.7 million for Q2 2026 from $9.2 million in Q2 2025.
• Research and development expenses increased by 75% to $26.3 million for Q2 2026.
• Selling, general, and administrative expenses increased by 42% to $44.8 million for Q2 2026.
• An asset impairment charge of $7.5 million was recorded in March 2026.
• The company continues to incur significant operating losses and expects to do so in the foreseeable future.
• Average sales price decreased due to a higher percentage of revenue cases from clinic/office-based accounts and increased volume rebates.

Risks

• The company has incurred significant net losses since inception and expects to continue incurring substantial losses in the foreseeable future, with no guarantee of achieving profitability.
• Revenue is heavily dependent on the success of Heartflow FFR CT Analysis and Heartflow Plaque Analysis, making it difficult to predict future prospects.
• Adoption of the Heartflow Platform may be negatively impacted if healthcare providers are unwilling to change standard practices or if third-party payors do not provide adequate coverage and reimbursement.
• The company faces risks associated with a concentrated customer base, although it expects new customers to decrease this risk over time.
• Significant competition exists in an environment of rapid technological change, and competitors may develop more effective products.
• The commercialization of Heartflow Plaque Analysis is nascent, and market acceptance is not guaranteed.
• Risks are associated with the use and development of AI models, including operational challenges, legal liability, and reputational concerns.
• Failure to properly manage future growth could harm the business.

Future Outlook

The company expects to continue to incur losses and expend significant cash in the foreseeable future due to scaling the business, investing in R&D, increasing sales and marketing efforts, and higher G&A costs associated with being a public company. Management believes current cash, cash equivalents, and investments, along with expected customer revenue, will be sufficient for at least the next 12 months.

Management Comments

• We believe that we are the most widely adopted AI-powered test for CAD.
• We believe the differentiated accuracy and clinical utility of our Heartflow Platform, along with its ability to enhance workflows, will continue to support our growth and advance the CCTA + Heartflow pathway as the definitive standard for the non-invasive diagnosis and management of CAD.
• We have experienced considerable revenue growth since we began commercializing the Heartflow Platform in 2015, driven primarily by growth in our account base and increasing test volumes at accounts in our installed base.
• We expect our research and development expenses to increase as we conduct clinical studies for expanded indications for use or to expand the addressable market populations for our products and to hire additional personnel to develop new product offerings and product enhancements.
• We expect that our selling, general and administrative expenses will increase in the future as a result of expanding our operations, including hiring personnel, to both drive and support anticipated growth as well as various incremental costs associated with operating as a public company.

Industry Context

StockSavvy.ai notes that Heartflow operates in the rapidly evolving medical technology sector, specifically focusing on AI-driven diagnostics for cardiovascular diseases. The company's performance is closely tied to the adoption rates of advanced diagnostic imaging techniques like CCTA and the integration of AI into clinical workflows. The increasing focus on precision medicine and non-invasive diagnostic solutions positions Heartflow favorably, but competition and reimbursement challenges remain key industry factors.

Comparison to Industry Standards

• Heartflow's revenue growth of 48% year-over-year in Q2 2026 outpaces many established medical device companies, but is in line with high-growth medtech startups.
• The company's gross margin of 83% is strong for a software-centric medical technology company, indicating efficient operations once revenue scales.
• The significant increase in R&D spending (75% YoY) reflects the industry trend of heavy investment in AI and new product development within the medtech space.
• The net loss, while increasing, is common for companies in this growth phase, prioritizing market penetration and product development over immediate profitability, a strategy seen across many innovative healthcare technology firms.

Legal Proceedings

• Heartflow filed a patent infringement lawsuit against Cleerly, Inc. on April 13, 2026, alleging infringement of six patents.
• The company and certain employees received civil investigative demands (CID) in October 2025 from the U.S. Department of Justice related to an investigation under the federal Anti-Kickback Statute and Civil False Claims Act. The outcome is uncertain and could materially impact the business.

Stakeholder Impact

• Shareholders: Increased revenue and gross margin are positive, but the widening net loss and increased operating expenses may be a concern for profitability.
• Employees: Continued investment in R&D and sales/marketing suggests potential for growth and job creation, alongside stock-based compensation expenses.
• Customers (Healthcare Providers): The company's products aim to improve CAD diagnosis and management, potentially leading to better patient outcomes and more efficient clinical workflows.
• Payors: The company's efforts to secure and expand reimbursement coverage are critical for widespread adoption and revenue generation.

Next Steps

• Continue commercialization efforts for Heartflow Plaque Analysis, leveraging expanded reimbursement coverage.
• Increase adoption of the CCTA + Heartflow pathway among referring and reading physicians.
• Introduce new products, such as Plaque Tracker, anticipated in 2027.
• Enroll in three randomized clinical trials in the second half of 2026 focused on high-risk asymptomatic subpopulations.
• Continue to invest in R&D to expand product applicability and develop new offerings.
• Manage operating expenses to support anticipated growth and public company requirements.

Key Dates

Recommendation

Heartflow demonstrates strong revenue growth and improving gross margins, indicating successful market penetration and product acceptance. However, the increasing net loss, significant operating expense growth, and ongoing R&D investments, coupled with the uncertainty surrounding the DOJ investigation, warrant a cautious approach. While the long-term potential is evident, the current financial performance and legal risks suggest a 'hold' rating until profitability improves and legal uncertainties are resolved.

Keywords

Coronary Artery Disease, Heartflow FFR CT Analysis, Heartflow Plaque Analysis, Medical Technology, AI Diagnostics, Cardiology, CCTA, Healthcare Software